Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept to Present at Upcoming Conferences
NEW YORK, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis
OCA met the primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeks AESOP represents a successful proof of concept for OCA in a second cholestatic liver disease Conference call scheduled for 8:30 a.m. ET today NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
View HTML
Toggle Summary CONTROL Trial Shows Statin Therapy Reversed LDL Increases to Below Baseline Levels in NASH Patients Treated with OCA
  Low dose atorvastatin rapidly reversed OCA associated LDL changes Conference call scheduled for 8:30 am ET NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
Worldwide net Ocaliva ® (obeticholic acid or OCA) 2Q 2017 sales of $30.4 million AESOP Phase 2 trial in patients with PSC met its primary endpoint CONTROL trial met its objective, confirming statin co-administration with OCA reduces LDL to below baseline levels in patients with NASH Conference call
View HTML
Toggle Summary Intercept to Report Second Quarter 2017 Financial Results on July 31
NEW YORK, July 26, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its second quarter 2017
View HTML
Toggle Summary Intercept's Ocaliva® (obeticholic acid) Receives 2017 Galien Chemical Synthesis Drug Award in Italy
NEW YORK, June 22, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Ocaliva ® (obeticholic acid) has been
View HTML
Toggle Summary Intercept Announces New Data Analysis From FLINT Trial of OCA in NASH Patients with Type 2 Diabetes
Post-hoc analysis showed that patients with both type 2 diabetes and NASH had high rates of advanced fibrosis OCA-treated patients achieved statistically significant improvements in all histologic measures, including fibrosis New findings presented at the American Diabetes Association's Scientific
View HTML
Toggle Summary Health Canada Grants Approval for Ocaliva™ (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis (PBC)
Ocaliva represents the first new treatment option in over 20 years for PBC, an autoimmune liver disease that is the leading reason for liver transplantation in women in Canada 
View HTML
Toggle Summary Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva® (obeticholic acid)
NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has received a 2017
View HTML